巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Coherus BioSciences

    CHRS
    13.390
    0.480
    3.50%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Coherus BioSciences - 延遲價格・最後更新於 16/08 12:00
    最高位
    14.030
    最低位
    13.260
    開市價
    --
    前收市價
    13.875
    成交量(千)
    41.76
    成交額(百萬)
    5.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    1,040.73
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    19.320 - 5.600
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Coherus BioSciences
    證券代碼
    CHRS.US
    所屬板塊
    Biotechnology
    公司業務
    Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
    發行量
    77422970
    公司總部
    333 Twin Dolphin Drive, Suite 600
    公司電郵
    darrington@coherus.com
    公司電話
    +1 650 649-3530
    暫無內容

    關於

    Coherus BioSciences(CHRS.US)所屬的行業板塊為Biotechnology。
    Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.